logo
logo
1

Patient information

If your institution uses the HemSys software and database, you can contribute to research!

What is a Multidisciplinary Consultation Meeting or MCM?

The Ellye Association, Together Leukemia Lymphoma Hope, and the specialized clinical research network on Lymphoma LYSA collaborated to explain in a short video how a Multidisciplinary Consultation Meeting (MCM) takes place.

This video is available on the LymphoSite website in the section ‘Diagnosis, After examinations, the MCM’: https://www.lymphosite.fr/diagnostic/5/apres-les-examens-la-rcp.html.

The information it contains applies to all hematologic diseases managed within the HemSys software.

2

Supporting research

“The data recorded for your care can aid research and the development of new therapeutic solutions in the field of hematology.

The software contains two main types of data, all of which are protected and secured:

Identifiable data necessary for the doctors managing your care: only medical professionals handle this data.
Non-identifiable data that does not allow for personal identification: a disease name, a numerical examination result, etc.

The reuse of non-identifiable data entered into HemSys enables doctors and researchers to study various hematological diseases. The HemSys database allows for concurrent sub-studies addressing specific research questions: number of new patients diagnosed per year, demographics of a pathology (distribution of ages and genders of patients), key biological markers, etc.”

What are the objectives of the studies conducted with data from the HemSys database?

The studies conducted using HemSys data will aim at improving medical practices, conducting research, fostering development, and fostering innovation in the field of hematology.
The studies or research will be reviewed by the HemSys governance to verify their scientific interest, the relevance of the methodology used, and the regulatory, legal, and technical feasibility, particularly regarding data security.

The studies can be conducted by various actors: the Carnot CALYM institute, hematologists, healthcare professionals, socio-economic actors, companies developing drugs, etc. All projects will be validated in advance for their scientific interest and conducted in accordance with current legislation to protect your data.

The studies will rely on the analysis of clinical data already contained in patients’ medical records. For example: the number of patients diagnosed with disease XXX in the year 2021.

The data analyzed in these studies will not allow for a direct link to patients’ identities as they are anonymized or pseudonymized (each person’s name is replaced by a unique number). The actors involved in this research cannot link this number to a patient’s identity.

Below is a table listing the conducted studies, the study sponsors, the scientific and/or medical contact, the data used, the analysis period, and the study timelines.

These studies involve patients for whom certain relevant medical data has been recorded in the HemSys database to be discussed in MCM. If you are being treated in a healthcare facility using the HemSys software and you have not objected to the digitization of your data and its reuse for research projects, this has no direct implications for you.

You have two options:

– If you do not oppose the use of your data for studies using HemSys data: you don’t need to take any action.
– If you wish to oppose the use of your data for one, several, or all research projects: you should discuss this with the physician who informed you about the use of HemSys. This decision will have no impact on your medical care. You can also communicate your decision by writing an email to the following address: dpo@calym.org. You can find specific information in your information letter, on posters in waiting rooms, or from the medical staff in the hematology department of your healthcare center.

3

Consult the list of studies conducted using the database

Study/Project Name Description Data Controller Purpose of the Project Document
Transferability of HemSys Results Comparison of HemSys and PMSI data (national hospitalization database) to extrapolate the transferability of HemSys results at the regional and national levels Academic Validate the use of “real-world” data for research on hematological diseases Information Letter_2023_PMSI
Marginal Zone Lymphoma Statistical description of patients with Marginal Zone Lymphoma (MZL) in HemSys (G.Manson, C. Thieblemont) Industrial Analyze and understand patient management for a potential drug Information Letter_2022_MZL
NGS Impact in CLL Management NGS Impact in CLL Management (M. Ganard, C. Pastoret) – science thesis Academic Analyze and understand patient management
Cold Agglutinins Cold Agglutinins (P. Daufresne, T. Lamy) – science thesis Academic Analyze and understand patient management
Relapse Hodgkin treated with BV + Benda Relapse Hodgkin treated with BV + Benda (K. Bouabdallah) – under publication Academic Analyze and understand patient management
Myelitis & Hodgkin’s Disease Myelitis & Hodgkin’s Disease (K. Le Dû) – science thesis – under publication Academic Analyze and understand patient management
Lymphoma & Lupus Lymphoma & Lupus (JS. Allain) – science thesis – under publication Academic Analyze and understand patient management
DLBCL & DHAP/DHAC/DHAOx DLBCL & DHAP/DHAC/DHAOx (E. Gyan) – currently under publication Academic Analyze and understand patient management
Myeloma & Bone Complications Myeloma & Bone Complications (A. Meynier de Salinelles, O. Decaux) – science thesis – currently under publication Academic Analyze and understand patient management